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ABSTRACT
The aims of this study were to estimate the importance of vaccine failure (VF) in cases of mumps during
2002–2004 in the city of Novosibirsk, Western Siberia, Russia, and to genotype the responsible virus
strain. Mumps virus-speciﬁc RT-PCR testing of saliva was performed for 18 cases of mumps. Sera were
tested for IgM and IgG, IgG avidity, and the ability to neutralise a panel of mumps viruses, including the
Leningrad-3 mumps vaccine virus. Of the 12 patients for whom vaccination status was positively
determined, 11 showed serological evidence of primary VF. Sequence analysis of virus RNA ampliﬁed
from saliva revealed a genotype C2 virus in 2002, a genotype H2 virus in 2003, and both genotypes in
2004. Although several vaccinated patients were positive for mumps virus IgG at the time of ﬁrst
sampling, only nominal levels of neutralising antibody were detected, and these were effective in
neutralising the vaccine strain, but not genotype C and H mumps virus strains. These results suggest
that the majority of cases of mumps in vaccinees are caused by primary VF, deﬁned as either a lack of
seroconversion or a lack of IgG maturity, as based on avidity testing. The results also support the
hypothesis that sera of low neutralising antibody titre have a limited ability to neutralise heterologous
mumps virus strains, suggesting that antigenic differences between circulating and mumps vaccine
virus strains may play a role in cases of breakthrough infection. Consistent with previous reports,
mumps virus genotypes C and H continue to circulate in Novosibirsk.
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INTRODUCTION
Despite evidence of effective, long-lasting immu-
nity following natural infection or vaccination
[1,2], strains of wild-type mumps virus (MuV)
continue to circulate worldwide. Recently, two
unusually large mumps epidemics have been
reported, one in the UK in 2005, involving over
70 000 cases [3], and one in the USA [4], which
began in early 2006 and involved 5783 cases (the
background number of mumps cases in the USA
has been c. 250 annually for the past decade).
The mumps epidemic in the UK has been attrib-
uted mostly to a large cohort of unvaccinated
individuals, mostly of college age, who were not
eligible for vaccination during childhood. Simi-
larly, the 2006 US epidemic involved mostly
college-age students, and has been linked to an
insufﬁcient proportion of the population receiv-
ing the recommended two-dose schedule of
mumps-containing vaccine. In such situations, in
which herd-immunity may be lost, outbreaks or
epidemics are easily started.
The occurrence of sporadic mumps outbreaks
in populations with high vaccine coverage is also
a well-known phenomenon. These outbreaks are
usually attributed to pockets of unvaccinated
individuals and ⁄ or vaccine failure (VF), divided
into primary (lack of seroconversion) or secon-
dary (waning immunity) failure [5–8]. It has also
been suggested that antigenic differences between
MuV strains may allow certain strains to escape
neutralisation in vaccinees [7,9,10]. While this
phenomenon has been demonstrated in the
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laboratory (S. Rubin, personal communication),
conclusive evidence of a causal relationship
between virus strain-speciﬁc antigenic differences
and outbreaks or epidemics has not yet been
demonstrated. However, for surveillance of vac-
cine protection against mumps, it is important to
follow the distribution of different genotypes of
MuV and to measure the genotype-speciﬁc immu-
nity in the population. A prospective study to
monitor mumps cases was therefore initiated in
Novosibirsk, Western Siberia, Russia, in 2002–
2004.
Novosibirsk is a large city with a population of
c. 1.4 million inhabitants. The Leningrad-3 (L-3)
mumps vaccine has been used since 1984 in
Novosibirsk as part of the national immunisation
programme, and the mumps vaccine coverage
rate in Novosibirsk has been calculated at 95%.
The most widely circulating MuV strains in
Novosibirsk between 1994 and 2003 belonged to
genotypes C and H [11–14]. According to ofﬁcial
data, 142 cases of mumps were reported in
Novosibirsk during 2001, 189 cases in 2002, 24
cases in 2003, and 27 cases in 2004. The large
decrease in the number of cases in 2003 and 2004
is probably a reﬂection of the then-instituted
requirement for laboratory conﬁrmation of cases,
suggesting that MuV may not actually have
caused many of the cases reported before 2003.
Vaccination status was determined for all clin-
ical cases of mumps included in this study, and
saliva and acute and convalescent sera were
obtained. RT-PCR testing of saliva using primers
speciﬁc for the MuV SH gene was performed to
conﬁrm the presence of the virus and to identify
the virus genotype [15]. Sera were tested by
ELISA for IgM and IgG antibody titres, and for
IgG antibody avidity. In addition, sera were
tested for their ability to neutralise the vaccine
strain (L-3) and two wild-type viruses isolated
previously in Novosibirsk.
PATIENTS AND METHODS
Subjects
The SRC VB Vector Ethical Committee approved the study
(IRB00001360). Informed consent was obtained from the
parents of all children and from the adult patients. The
patients’ ages and their vaccination status, taken from the ofﬁ-
cial medical records, are presented in Table 1. In total, 18
patients (aged 3–56 years; six females, 12 males) were enrolled
in the study. Of the 18 patients, 12 (67%) had been immunised
with the L-3 mumps strain vaccine. All 18 patients were
diagnosed clinically with mumps according to the WHO case
deﬁnition (http://www.who.int/vaccines/globalsummary/
timeseries/tsincidenceMUM.htm). Clinical signs of meningitis
(severe headache, vomiting, nuchal rigidity) were observed in
patients P1 ⁄ 2002, P3 ⁄ 2003, P8 ⁄ 2004, P9 ⁄ 2004, P16 ⁄ 2004 and
P18 ⁄ 2004, but spinal taps were not performed; thus, the
diagnosis could not be conﬁrmed. Pancreatitis was diagnosed
Table 1. Serum levels of mumps virus (MuV) IgM, IgG, IgG avidity and neutralising antibody in mumps patients
Patient
Age
(years)
Statusa
(years)
Days
sera were
takenb
Serum
IgM
Serum IgG
(titre)
IgG
avidity
(%)
PRN
L-3
(titre)
PRN
H
(titre)
PRN
C
(titre) RT-PCRc
MuV
genotype
P1 ⁄ 2002 8 R (1.5) 5 ⁄ 26 + ⁄ – 1:900 ⁄ 1:2000 27 1:4 ⁄ 1:8 0 ⁄ 1:4 0 ⁄ 1:8 + ⁄ – C
P2 ⁄ 2002 4 V (2.5) 5 ⁄ 26 + ⁄ – 1:2000 ⁄ 1:8200 31 1:4 ⁄ 1:4 0 ⁄ 0 0 ⁄ 1:8 + ⁄ – C
P3 ⁄ 2003 18 V (4) 5 ⁄ 11 ⁄ 27 – ⁄+ ⁄ – neg ⁄neg ⁄ 1:500 ND ⁄ 8 0 ⁄ 1:4 0 ⁄ 1:8 0 ⁄ 0 + ⁄+ ⁄ – H
P4 ⁄ 2003 16 R (4) 4 ⁄ 26 + ⁄ – 1:1500 ⁄ 1:9000 29 1:4 ⁄ 1:4 0 ⁄ 1:8 0 ⁄ 0 + ⁄ – H
P5 ⁄ 2003 15 R (4) 5 ⁄ 26 + ⁄ – 1:8500 ⁄ 1:17 300 26 1:4 ⁄ 1:4 0 ⁄ 1:8 0 ⁄ 0 + ⁄ – H
P6 ⁄ 2003 25 V (4) 5 ⁄ 26 + ⁄ – 1:5700 ⁄ 1:11 800 30 1:4 ⁄ 1:8 0 ⁄ 1:8 0 ⁄ 1:4 + ⁄ – H
P7 ⁄ 2004 17 Unknown 5 ⁄ 26 + ⁄ – 1:600 ⁄ 1:1300 32 1:4 ⁄ 1:8 0 ⁄ 1:8 0 ⁄ 1:4 + ⁄ – H
P8 ⁄ 2004 49 NV 5 ⁄ 26 + ⁄ – neg ⁄ 1:800 ND ⁄ 10 0 ⁄ 0 0 ⁄ 1:4 0 ⁄ 0 + ⁄ – H
P9 ⁄ 2004 20 V (5) 4 ⁄ 26 + ⁄ – neg ⁄ 1:300 ND ⁄ 6 0 ⁄ 1:4 0 ⁄ 1:8 0 ⁄ 0 + ⁄ – H
P10 ⁄ 2004 17 Unknown 5 ⁄ 26 + ⁄ – 1:500 ⁄ 1:900 32 1:4 ⁄ 1:4 0 ⁄ 1:4 0 ⁄ 0 + ⁄ – H
P11 ⁄ 2004 35 NV 2 ⁄ 25 + ⁄ – neg ⁄ 1:500 ND ⁄ 11 0 ⁄ 0 0 ⁄ 1:4 0 ⁄ 0 + ⁄ – H
P12 ⁄ 2004 9 R (2.5) 3 ⁄ 25 + ⁄ – 1:1400 ⁄ 1:3000 27 1:4 ⁄ 1:8 0 ⁄ 1:8 0 ⁄ 1:4 + ⁄ – H
P13 ⁄ 2004 28 V (5) 5 ⁄ 26 + ⁄ – 1:1400 ⁄ 1:3000 28 1:4 ⁄ 1:8 0 ⁄ 1:8 0 ⁄ 1:4 + ⁄ – H
P14 ⁄ 2004 18 V (5) 5 ⁄ 26 + ⁄ – neg ⁄ 1:300 ND ⁄ 4 0 ⁄ 0 0 ⁄ 1:4 0 ⁄ 0 + ⁄ – H
P15 ⁄ 2004 22 V (5) 5 ⁄ 26 + ⁄ – 1:300 ⁄ 1:800 29 1:4 ⁄ 1:4 0 ⁄ 1:4 0 ⁄ 0 + ⁄ – H
P16 ⁄ 2004 30 NV 3 ⁄ 24 + ⁄ – neg ⁄ 1:1000 ND ⁄ 14 0 ⁄ 1:4 0 ⁄ 1:4 0 ⁄ 1:8 + ⁄ – C
P17 ⁄ 2004 3 V (2) 3 ⁄ 25 + ⁄ – 1:1500 ⁄ 1:3000 34 1:8 ⁄ 1:8 0 ⁄ 1:4 0 ⁄ 1:8 + ⁄ – C
P18 ⁄ 2004 56 NV 3 ⁄ 24 + ⁄ – neg ⁄ 1:500 ND ⁄ 13 0 ⁄ 1:4 0 ⁄ 0 0 ⁄ 1:8 + ⁄ – C
aVaccination status: V, vaccinated with one dose; R, re-vaccinated (two doses); NV, not vaccinated. Figures in parentheses indicate the time (years) since the most recent
vaccination.
bRelative to day of fever onset. The ﬁrst sample was taken upon admission to the hospital and the second was taken following discharge (except P3 ⁄ 2003).
cRT-PCR results are shown for saliva samples.
PRN, plaque reduction neutralisation assay; ND, not detectable; neg, negative.
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in patient P12 ⁄ 2004. The duration of the clinical course
of mumps infection was 7–14 days. All patients recovered
completely.
Serological methods
Acute and convalescent paired serum and saliva samples
were obtained from all patients. Serological detection of anti-
MuV IgM and IgG was done by ELISA (Enzygnost; Dade
Behring, Marburg, Germany). Assessment of IgG avidity was
used to differentiate between primary vaccine failure (PVF)
and secondary vaccine failure (SVF). IgG avidity was
measured using the IgG ELISA and 6 M urea as described
previously [16]. According to the manufacturer’s instruction,
OD values of 0.1–2.5 allow calculation of IgG titres. Thus,
avidity was also determined within this OD range. Samples
with OD values <0.1 were regarded as not detectable, and
samples with OD values >2.5 were diluted appropriately
and retested. The avidity index (AI) was calculated as the
ratio of the absorbance with and without urea treatment.
Using a system established previously, an AI £31 was
considered to represent low avidity, while values ‡32 were
considered to represent high avidity [16].
Other aetiologies were excluded by testing serum for
antibodies to parainﬂuenza virus types 1–3 and Epstein–Barr
virus (EBV) [17]. IgG to the parainﬂuenza viruses was
measured with a commercial enzyme immunoassay kit able
to detect all three types of parainﬂuenza virus (Parainﬂuenza
1 ⁄ 2 ⁄ 3 IgG-ELISA; Immuno Biological Laboratories, Hamburg,
Germany). IgM antibodies to EBV were measured with a
commercial enzyme immunoassay kit (Enzygnost Anti-EB-
V ⁄ IgM; Dade Behring). Any patient who was IgM-positive for
EBV was also tested for IgG to EBV.
Neutralising anti-MuV antibody titres were determined
using a plaque reduction neutralisation (PRN) assay, with the
L-3 MuV vaccine strain (kindly provided by the Tarasevich
State Institute of Standardisation and Control of Immuno-
biological Preparations, Moscow, Russia) and wild-type
MuVs of genotypes H (strain PetroNov, accession no.
AY681495) and C (strain Dragoon, accession no. AY669145)
as the targets. The wild-type MuVs of genotypes C and H
were isolated in Novosibirsk, Russia in 1994 [13] and 2003
[14], respectively. In brief, sera were heat-inactivated at
56C for 45 min. Two-fold serial dilutions of heat-inactivated
serum (or medium alone as a negative control) were
mixed with equal volumes containing 25–35 PFU of the target
virus to give a ﬁnal sera dilution range of 1:4–1:128. Serum–
virus mixtures were incubated at 37C in CO2 5% v ⁄v for 1 h
and then placed on Vero cell monolayers in 24-well plates and
incubated for 1 h at 37C in CO2 5% v ⁄v. The virus–serum
mixture was removed by aspiration and the cell monolayers
were rinsed with MEM (Quality Biologicals, Gaithersburg,
MD, USA) immediately before covering with Nobel agar
(BD Difco, Franklin Lakes, NJ, USA) 0.75% w ⁄v in 2 · MEM
(Quality Biologicals) supplemented with fetal bovine serum
10% v ⁄v. Plates were then incubated at 37C in CO2 5% v ⁄v
for 5 days. A second layer of agar containing neutral red
(Quality Biologicals) 0.01% w ⁄v was added and incubated
overnight for visualisation of the plaques. For each serum, the
neutralising antibody titre was deﬁned as the highest dilution
capable of reducing the number of virus plaques by ‡50%
compared to control values. The cut-off for seropositivity was
a neutralising antibody titre of ‡1:4.
Mumps PRN titres were normalised by logarithmic trans-
formation to calculate mean titres (MT). Quantitative
results were expressed as MT ± SD (standard deviation). The
statistical signiﬁcance between MT was tested using Student’s
t-test or chi-square tests, with p £0.05 considered to be
signiﬁcant.
RT-PCR and sequencing
RNA was extracted and puriﬁed from throat swabs and sera
using an RNeasy Mini Kit (Qiagen, Hilden, Germany),
followed by reverse transcription using a Titan One Tube
RT-PCR System (Roche, Mannheim, Germany). The primers
for RT-PCR and sequencing were speciﬁc for the SH gene,
as described previously [13,18,19]. Primer 1 (sense),
5¢-TCAACACAATATCAAGTA (positions 2964–2981), and
primer 2 (antisense), 5¢-TTCTGTGTTGTATTGTGA (positions
3401–3418), were used for RT-PCR. The PCR products were
excised from the gel and puriﬁed using a QIAquick Gel
Extraction Kit (Qiagen). The puriﬁed products were directly
sequenced using primer 3 (sense), 5¢-ATGATCTCATCAGG-
TAC (positions 2988–3004), and primer (antisense),
5¢-TCCTAAGTTTGTTCTGG (positions 3384–3400), for
sequencing. Nucleotide sequences were determined using a
CEQ 2000 Dye Terminator Cycle Sequencing Kit and a CEQ
2000 XL DNA Analysis System (Beckman Coulter, Fullerton,
CA, USA) according to the manufacturer’s instructions.
Nucleotide alignments were performed using the Vector
NTI v.8.0 (InforMax, Bethesda, MD, USA) software package.
Deﬁnitions
PVF was deﬁned as a previously vaccinated subject with a
clinical diagnosis of mumps and evidence of a primary
immune response, i.e., IgM-positive ⁄ IgG-negative, or IgG-
positive with low avidity [20]. SVF was deﬁned as a previously
vaccinated subject with a clinical diagnosis of mumps and
evidence of a secondary immune response, i.e., high-avidity
IgG antibody in acute-phase sera [16].
RESULTS
Serum levels of IgM and IgG to MuV, IgG avidity,
neutralising antibody titres and RT-PCR results
are summarised in Table 1. All patients were
negative for EBV, with the exception of P18 ⁄ 2004,
who suffered from an acute severe course of the
mixed infection. All patients were negative for
parainﬂuenza viruses 1, 2 and 3, based on enzyme
immunoassay tests as described above.
Serological results: estimation of immune
response
MuV-speciﬁc IgM antibodies were detected at
admission for all patients. There was no correla-
tion between IgM and vaccination status, or
between IgG levels in acute-phase sera and
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vaccination status. Seven patients were IgG-neg-
ative at the acute phase of the disease, although
three of these patients had been vaccinated
previously. Of the six patients with symptoms of
meningitis (P1 ⁄ 2002, P3 ⁄ 2003, P8 ⁄ 2004, P9 ⁄ 2004,
P16 ⁄ 2004 and P18 ⁄ 2004), ﬁve were initially sero-
negative. Unexpectedly high initial IgG levels
were found in P5 ⁄ 2003 and P6 ⁄ 2003.
Both of the patients of unknown vaccination
status (P7 ⁄ 2004, P10 ⁄ 2004) appeared to have
developed a secondary immune response, based
on the results of IgG avidity testing. Four patients,
P8 ⁄ 2004, P11 ⁄ 2004, P16 ⁄ 2004 and P18 ⁄ 2004, being
unvaccinated, were seronegative at admission,
and thereafter were considered to have developed
a primary immune response. Taking into account
a low AI or IgG negativity, the vaccinated patients
P1 ⁄ 2002–P6 ⁄ 2003, P9 ⁄ 2004 and P12 ⁄ 2004–P15 ⁄ 2004
were considered to be cases of PVF. Thus, only
one of the 12 vaccinated patients, P17 ⁄ 2004,
showed evidence of SVF, characterised by a high
AI, and also by the highest PRN titre against the
L-3 vaccine virus.
The PRN assay results were very informative in
characterising VFs. Acute-phase sera from all IgG-
positive vaccinated patients with PVFs showed
equally low titres of neutralising antibodies (1:4) in
the PRN assay with the L-3 vaccine virus as the
virus target. The acute-phase sera from all patients
in this study lacked neutralising activity against
wild-type MuV of both genotypes C and H.
However, all 13 patients infected with a genotype
H MuV strain had PRN activity against the
genotype H virus (MT ± SD = 2.61 ± 0.47 –log2
dilution) at discharge, and only four (31%) of these
13 patients had PRN activity against the genotype
C virus (MT ± SD = 0.62 ± 0.89 –log2 dilution)
(p <0.005). Similarly, of the ﬁve patients infected
by the genotype C virus, all ﬁve had PRN activity
against the genotype C virus (MT ± SD =
3.0 ± 0.0 –log2 dilution), but only three (60%) had
activity against the genotype H virus (MT ± SD =
1.2 ± 0.89 –log2 dilution; p <0.002) at discharge.
Nine (50%) of the subjects showed increased PRN
titres against the L-3 vaccine MuV at discharge
(1.28 ± 1.02 –log2 dilution vs. 2.0 ± 0.97 –log2 dilu-
tion; p <0.05). It should be noted that themeasured
PRN titres in the convalescent sera may be
artiﬁcially low, since these sera were drawn 3–4
weeks following the onset of symptoms (Table 1).
Longer post-exposure periods (2–3 months) are
probably needed to reach peak titres.
The only difference observed when comparing
the immune responses of patients vaccinated with
one or two doses of mumps vaccine was that IgG
was not detected in acute-phase sera from three of
the eight patients who received one dose of
vaccine, whereas IgG was detected in acute-phase
sera from all four patients who received two
doses of vaccine. All other parameters assessed
were similar. All patients, regardless of the
number of vaccine doses received, were IgM-
positive at the time of hospital admission. With
the exception of the IgG-negative patients, the
mean IgG titre in acute-phase sera of one-dose
vaccinees (1:2180) did not differ statistically from
that of two-dose vaccinees (1:3075), and both of
these means increased, by 3-fold and 2.6-fold,
respectively, by the time of the second blood
sample approximately 21 days later. The mean
IgG AI measured in the one-dose vs. two-dose
vaccinees was also similar (30.4 vs. 27.3), as were
the PRN titres. All patients in both groups were
considered to be cases of PVF, with the exception
of P17 (a one-dose vaccinee assessed as a case of
SVF). However, these ﬁndings were based on
only a small number of subjects per study group
(eight one-dose and four two-dose vaccinees), and
the results may not be representative.
RT-PCR results, nucleotide sequence analysis
and assignment to genotype
The clinical diagnosis of all 18 cases of mumps
was conﬁrmed by RT-PCR (Table 1). Five
(P1 ⁄ 2002, P2 ⁄ 2002, P16 ⁄ 2004, P17 ⁄ 2004, P18 ⁄ 2004)
of the 18 patients had been infected with a
genotype C MuV (based on the SH gene se-
quence). The nucleotide sequences obtained from
these patients were each identical to the Dragoon
strain used in the PRN assays, which was isolated
in Siberia several years previously (accession no.
AY669145) [13]. Based on phylogenetic analysis,
the genotype C MuV isolated in Novosibirsk in
2002 and in 2004, as well as the Dragoon strain,
belonged to subgenotype C2 [15,21].
The other 13 SH gene sequences (P3 ⁄ 2003–
P15 ⁄ 2004) belonged to genotype H. The sequences
obtained from these patients were identical to each
other and to the sequence of PetroNov, sequenced
previously in Siberia [14] (accessionno.AY681495).
Based on phylogenetic analysis, the genotype H
MuV isolated in Novosibirsk during 2003–2004
belonged to subgenotype H2 [21].
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DISCUSSION
Co-circulation of genotypes H2 and C2 was
identiﬁed during the study period. This is the
ﬁrst report of the H2 genotype in Novosibirsk.
The genotype C MuV has been associated previ-
ously with a small (64 cases) outbreak in Novo-
sibirsk during 1994 [13]. The SH gene sequence of
the genotype C2 MuV strain reported here is
identical to that of the 1994 outbreak. Genotypes
H2 and C2 both caused only sporadic cases of
mumps infection during 2002–2004. Notably, 44%
of all registered mumps cases in Novosibirsk
during 2004 were included in this investigation.
RT-PCR analysis is indispensable for conﬁrma-
tion of the diagnosis of mumps in highly vaccin-
ated populations [22]. This is highlighted by the
serological data in the present study, which
showed that, in many cases, mumps patients
have substantial levels of virus-speciﬁc IgG at the
time of ﬁrst sampling, and do not show the
customary four-fold increase in titre in convales-
cent sera. Despite high ELISA-based MuV-speciﬁc
IgG titres in acute-phase sera in some patients,
IgG avidity was typically low. This absence of an
association between IgG titres and IgG avidity has
been reported previously for a number of infec-
tious agents, including MuV [22–26], and empha-
sises the importance and relevance of avidity
testing in investigating vaccine failures.
It is important to emphasise that serum anti-
body is but one facet of the immune response.
Thus, testing of IgG should be interpreted with
caution. The measurement of IgG avidity (func-
tional afﬁnity) is critical in differentiating PVF
from SVF, and provides important information
for improving the mumps prevention strategy
[27], e.g., a second dose of mumps-containing
vaccine [28]. Vaccine failures are far less common
in recipients of a two-dose regimen [29,30]. In
eight of the 12 cases of VF identiﬁed in this study,
only one dose of vaccine had been administered,
and PVF was identiﬁed in all eight of these cases.
A mandatory second vaccination was not intro-
duced in Novosibirsk until 1999.
It is also important to note that the incubation
period for mumps is ‡3 weeks, and the possibility
that the observed ELISA-based levels of IgG in
acute-phase sera are, in part, a response to
exposure to the wild-type virus (as opposed to
being solely a vaccine response) can therefore not
be ignored. Also, the question of whether the
presence of high (borderline) avidity IgG in acute-
phase sera in vaccinees is conclusive evidence of
SVF will require further investigation. However,
this does not appear to be a signiﬁcant issue in
this study, since IgG avidity-based SVF was
assigned to only one of the subjects investigated.
Also critical is the examination of neutralising
antibody activity. An important ﬁnding in the
present study was that all patients initially lacked
neutralising antibody activity against the C2 and
H2 viruses, but that the majority of these patients
were able to neutralise the vaccine strain. Such
apparent strain-speciﬁc immunity has been report-
ed previously, especially in cases with low-titre
sera, and it has been suggested that this phenom-
enon is responsible for cases of breakthrough
infection in vaccinees [31]. In general, the majority
of the patients in the present study failed to
induce markers suggestive of a mature functional
immune response; e.g., they had low IgG avidity
and low sera-neutralising activity, and thus,
not surprisingly, mounted primary immune
responses despite a history of vaccination. These
data are consistent with ﬁndings in a previous
study of horizontal transmission of the L-3
vaccine virus [22]. The present data demon-
strate a MuV strain-speciﬁc neutralising antibody
response, in that all convalescent sera could
neutralise an MuV genotype similar to the one
detected by RT-PCR in patient saliva, but were
often unable to neutralise a different contempor-
ary wild MuV genotype.
The goal of vaccination is the generation of a
memory response that can rapidly clear infection,
thus providing protection to the host. A signiﬁ-
cant effort has been made towards identifying the
attributes of the immune response that are asso-
ciated with optimal protection. As humoral and
cellular immune responses to vaccination play
important roles in protection, both must be
considered when examining a possible surrogate
marker or indicator of protection, as has been
described previously for measles virus [32–35].
Earlier ﬁndings [22], as well as those presented
here, support the hypothesis that a combination
of high virus-speciﬁc IgG avidity (‡32%) and at
least a nominal level of neutralising activity (‡1:8)
decreases the risk of mumps infection, even
among close contacts. Taken together, the sero-
logical and virological ﬁndings described here
highlight the importance of the speciﬁc methods
employed in case investigation and in assessing
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VF. A VF case investigation protocol should also
consider the inﬂuence of the speciﬁc virus strains
used in the serological IgG avidity and PRN
assays [36]. The latter is very important in
understanding the correlation between the mat-
uration of mumps-speciﬁc IgG after infection or
immunisation and the neutralising capacity spec-
trum of immune sera. Notably, antibody avidity
testing appears to be a particularly useful assay
for examining potential cases of VF.
In conclusion, only one dose of vaccine had
been administered to the majority of cases of VF
identiﬁed in this study, and primary VF was
implicated in most of these cases, based on a
failure to induce markers suggestive of a mature
and functional immune response. Whether the
absence of sufﬁcient titres of neutralising anti-
body in response to vaccination, or the absence
of neutralising antibody speciﬁc for the endemic
MuV strain, was responsible for susceptibility of
vaccinees to infection cannot be determined
conclusively, but both are indicated. What is
clear is that causes of VF are complex and
multifactorial in nature. A proper assessment of
VFs should include IgG avidity testing, as well
as a comprehensive assessment of the functional
antibody response, i.e., the differential ability of
serum antibody to neutralise both the vaccine
virus and the endemic challenge virus strains.
Other protective responses not captured in this
analysis of VFs include cellular and mucosal
responses. Such responses deserve more atten-
tion and may further clarify the occurrence
of VFs.
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